Latest Filings

Issuer Activity

Insider Overview :: QLT Inc. (T:QLT) [?]
Business Focus: Biotechnology & Medical Research
This company is also listed in the United States as QLTI on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.
Recent Price for QLT
CAD 8.17 0.00 (0.00%)
TSX Delayed 15 minutes
May 22 1547 EDT
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
N/A 9.20 0.0 N/A 412.83
1-Day Low 52-Week Low Yield Avg. Volume  
N/A 6.82 0.0% 13,777  
Log in or sign up for a free account to add this stock to your watch list.
Holdings trends & enhanced charts available in PDF report. Click here for details »
Latest 10 SEDI filings (by transaction date) for QLT within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 22nd, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
May 22/13 May 17/13 Aryeh, Jason Indirect Ownership Short Put Option (obligation to buy) 70 - Acquisition (writing) of third party derivative 37 $0.400
USD
May 22/13 May 17/13 Aryeh, Jason Indirect Ownership Short Put Option (obligation to buy) 70 - Acquisition (writing) of third party derivative 50 $0.400
USD
May 14/13 May 14/13 Jagpal, Sukhi Direct Ownership Common Shares 10 - Disposition in the public market -100 $8.08
May 14/13 May 14/13 Jagpal, Sukhi Direct Ownership Common Shares 10 - Disposition in the public market -9,900 $8.07
May 14/13 May 14/13 Jagpal, Sukhi Direct Ownership Common Shares 51 - Exercise of options 10,000 $7.23
May 14/13 May 14/13 Jagpal, Sukhi Direct Ownership Options 51 - Exercise of options -10,000  
May 14/13 May 13/13 Kozarich, John W. Direct Ownership Common Shares 10 - Acquisition in the public market 3,981 $7.98
USD
May 14/13 May 13/13 Kozarich, John W. Direct Ownership Common Shares 10 - Acquisition in the public market 2,000 $7.96
USD
May 14/13 May 13/13 Kozarich, John W. Direct Ownership Common Shares 10 - Acquisition in the public market 200 $7.97
USD
May 14/13 May 13/13 Kozarich, John W. Direct Ownership Common Shares 10 - Acquisition in the public market 3,819 $7.96
USD
This company is also listed in the United States as QLTI on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Latest 10 SEDI filings (by filing date) for QLT within the last 6 months [?]
Amended Filing
As of 11:59pm ET May 22nd, 2013
Filing
Date 		Transaction
Date 		Insider Name Ownership
Type 		Securities Nature of transaction # or value acquired or disposed of Price
May 22/13 May 17/13 Aryeh, Jason Indirect Ownership Short Put Option (obligation to buy) 70 - Acquisition (writing) of third party derivative 37 $0.400
USD
May 22/13 May 17/13 Aryeh, Jason Indirect Ownership Short Put Option (obligation to buy) 70 - Acquisition (writing) of third party derivative 50 $0.400
USD
May 14/13 Jun 4/12 Aryeh, Jason Indirect Ownership Short Put Option (obligation to buy) 00 - Opening Balance-Initial SEDI Report    
May 14/13 May 14/13 Jagpal, Sukhi Direct Ownership Common Shares 10 - Disposition in the public market -100 $8.08
May 14/13 May 14/13 Jagpal, Sukhi Direct Ownership Common Shares 10 - Disposition in the public market -9,900 $8.07
May 14/13 May 14/13 Jagpal, Sukhi Direct Ownership Common Shares 51 - Exercise of options 10,000 $7.23
May 14/13 May 14/13 Jagpal, Sukhi Direct Ownership Options 51 - Exercise of options -10,000  
May 14/13 May 13/13 Kozarich, John W. Direct Ownership Common Shares 10 - Acquisition in the public market 3,981 $7.98
USD
May 14/13 May 13/13 Kozarich, John W. Direct Ownership Common Shares 10 - Acquisition in the public market 2,000 $7.96
USD
May 14/13 May 13/13 Kozarich, John W. Direct Ownership Common Shares 10 - Acquisition in the public market 200 $7.97
USD
This company is also listed in the United States as QLTI on the NASDAQ. Click here to see if there are any SEC insider filings on insidertracking.com.

Sign up for an account or login above to see all SEDI filings within the past 6 months.
Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider.
No Markers (TSX Insider Summaries) for QLT on May 22, 2013 [?]
To view marker data for the past week, sign up for an account or log in above.
To view more history, sign up for an account at inkresearch.com
Sector:  Healthcare Industry:  Biotechnology & Medical Research
Key People
Jason M. Aryeh
Chairman of the Board 		Sukhi Jagpal
Interim Chief Financial Officer, Interim Chief Accounting Officer 		Alexander R. Lussow
Senior Vice President - Commercial Operations and Business Development
Christopher A. Muller
Chief Commercial Officer of QLT Ophthalmics, Inc. 		   
Company Contact
Address: Suite 101, 887 Great Northern Way
VANCOUVER BC V5T 4T5
Tel: 1-604-7077571
Website: www.qltinc.com
IR: phx.corporate-ir.net/phoenix.zhtml?c=67181&p=irol-irhome
Business Overview
QLT Inc., is a biotechnology company. The Company is engaged in the development and commercialization of ocular products. It develops QLT091001, a synthetic retinoid compound for the potential treatment of certain inherited retinal degenerative diseases. In September 2012,it sold all of its assets related to Visudyne to Valeant Pharmaceuticals International, Inc. (Valeant). It also sold Qcellus laser and certain other photodynamic therapy intellectual property, In April 2013, it sold its punctal plug drug delivery system (PPDS) technology (Technology) to Mati Therapeutics Inc. (Mati). It is engaged in providing transition services to Valeant concerning most of the aspects of the Visudyne and Qcellus laser business. It is conducting Phase Ib clinical proof-of-concept studies of QLT091001, a synthetic retinoid replacement therapy for 11-cis-retinal, a key biochemical component of the visual retinoid cycle, in patients with Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
Competitors with Recent Insider Filings
EnWave (V:ENW)
iCo Therapeutics (V:ICO)
Sirona Biochem (V:SBM)
 
QLT Inc. Insider Report Only $20.00